Loading…
Surrozen, Inc. is projected to rise to $28.75 by 2027, a +29% move from its current price of $22.21. SRZN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $21.45 | $22.23 | $23.03 | +0.07% |
| Aug 4 | $21.15 | $22.24 | $23.39 | +0.14% |
| Aug 5 | $20.93 | $22.26 | $23.67 | +0.22% |
| Aug 6 | $20.75 | $22.27 | $23.91 | +0.29% |
| Aug 7 | $20.59 | $22.29 | $24.13 | +0.36% |
| Aug 8 | $20.45 | $22.31 | $24.33 | +0.43% |
| Aug 9 | $20.32 | $22.32 | $24.52 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $20.32 | $22.32 | $24.52 | +0.50% |
| Week 2 | $19.65 | $22.43 | $25.62 | +1.01% |
| Week 3 | $19.17 | $22.55 | $26.52 | +1.52% |
| Week 4 | $18.79 | $22.66 | $27.33 | +2.03% |
| Week 5 | $18.47 | $22.77 | $28.09 | +2.54% |
| Week 6 | $18.19 | $22.89 | $28.80 | +3.06% |
| Week 7 | $17.95 | $23.00 | $29.48 | +3.58% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Surrozen, Inc. is a biotechnology company focused on discovering and developing product candidates that selectively modulate the Wnt pathway for tissue repair. Its lead antibody-based therapeutics target various disease areas, including eye diseases, intestinal and retinal conditions, liver and kidney disorders, and other tissues.
The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and VEGF antagonism to treat diabetic macular edema, neovascular age-related macular degeneration, and retinopathy indications; SZN-8143, which adds interleukin-6 to the mix for similar retinal indications; and SZN-413, a Fzd4-targeted bi-specific antibody for retinal vascular diseases. Surrozen has collaboration with Boehringer Ingelheim to research, develop, and commercialize Fzd4 bi-specific antibodies, and a research collaboration with TCGFB to discover antibody therapeutics targeting TGF-ß for idiopathic pulmonary fibrosis. The company was founded in 2015 and is headquartered in South San Francisco, California.
Surrozen operates within the Healthcare sector and trades under the SRZN ticker. Its focus on Wnt pathway modulation and antibody-based approaches situates it in the innovative biotech space dedicated to tissue repair and retinal therapies.
Surrozen, Inc. (SRZN) is a biotechnology company engaged in discovering and developing therapies that modulate the Wnt pathway for tissue repair. The stock is currently priced at $20.83 with a market cap of $241.84M and a listed rank of 3457.
The company’s near-term forecast shows a 2026 average price of $20.83, with a range from $17.98 to $29.78 and a 0% ROI, signaling neutral sentiment in the year.
Looking further out, the forecast turns increasingly bullish, with 2027 through 2035 showing rising average prices and higher ROIs, culminating in a 2030 average of $32.26 and a 54.9% ROI, and a 2050 average of $151.07 with a 625.3% ROI. The bullish sentiment intensifies across the longer horizon, reflecting an expected growth trajectory for SRZN based on the provided numbers.
A major floor 29.3% below — a decisive break under it would weaken the trend.
The nearest floor, 13.6% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 53.7% above — clearing it would confirm fresh momentum.
Key SRZN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SRZN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.29 | Buy | $20.88 | Buy |
| MA 10 | $20.92 | Buy | $20.99 | Buy |
| MA 20 | $21.73 | Buy | $21.69 | Buy |
| MA 50 | $23.35 | Sell | $23.39 | Sell |
| MA 100 | $26.13 | Sell | $24.09 | Sell |
| MA 200 | $22.81 | Sell | $22.33 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.25 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 28.31 | Neutral |
| Williams %R (14) | -20.58 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 1.93 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 79.42 | Neutral |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -2.54 | Sell |
| Ultimate (7,14,28) | 51.14 | Neutral |
| Momentum (10) | 0.25 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 20.27 | Buy |
| ADX (14) | 19.35 | Neutral |
| ATR (14) | 0.76 | Info |
Technical snapshot for the last 30 days shows a neutral posture. RSI(14) is 40, indicating neither overbought nor oversold conditions. The stock trades near the 50-day simple moving average (SMA50) at $23.42 and above the 200-day simple moving average (SMA200) at $22.77.
Support is cited at $19.20 and resistance at $25.95, framing a 30-day price range between $16.64 and $26.08. The annualized volatility is high at 70%, underscoring substantial near-term fluctuations.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.98 | $22.21 | $31.94 | 0% | Neutral | |
| $22.31 | $28.75 | $39.52 | +29% | Bullish | |
| $23.65 | $31.65 | $45.60 | +43% | Bullish | |
| $24.37 | $33.67 | $50.29 | +52% | Bullish | |
| $25.13 | $35.70 | $54.96 | +61% | Bullish | |
| $25.08 | $36.56 | $57.77 | +65% | Bullish | |
| $32.35 | $48.29 | $78.11 | +117% | Bullish | |
| $39.66 | $60.56 | $100.04 | +173% | Bullish | |
| $38.55 | $60.17 | $101.32 | +171% | Bullish | |
| $41.37 | $65.92 | $113.00 | +197% | Bullish | |
| $59.37 | $104.16 | $192.26 | +369% | Bullish | |
| $85.43 | $178.15 | $365.63 | +702% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $17.98 | $22.21 | $28.46 | +0.00% |
| September 2026 | $20.27 | $24.19 | $29.82 | +8.90% |
| October 2026 | $19.69 | $23.71 | $29.64 | -1.97% |
| November 2026 | $19.79 | $24.00 | $30.33 | +1.22% |
| December 2026 | $20.49 | $25.02 | $31.94 | +4.25% |
Click any year to see its month-by-month SRZN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Surrozen, Inc.'s 2026 outlook centres on $22.21, within a $17.98 to $31.94 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SRZN could reach as high as $39.52, with a base case around $28.75 and support toward $22.31 — roughly +29% from $22.21. Buyers look set to stay in control over this stretch.
Expect SRZN to range from $23.65 to $45.60 through 2028. The $31.65 average target implies a +43% move from current prices. That is up +10% on the projected 2027 average. Momentum favours further upside here.
The SRZN price prediction for 2029 points to an average of $33.67 (low $24.37, high $50.29) — a potential gain of +52% on today's $22.21. Buyers look set to stay in control over this stretch.
In 2030, SRZN is projected to trade between $25.13 and $54.96, averaging $35.70 — a potential gain of +61% from today's $22.21. That is up +6% on the projected 2029 average. Momentum favours further upside here.
Surrozen, Inc.'s 2031 outlook centres on $36.56, within a $25.08 to $57.77 range. That is up +2% on the projected 2030 average. That marks a +65% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, SRZN could reach as high as $78.11, with a base case around $48.29 and support toward $32.35 — roughly +117% from $22.21. Momentum favours further upside here.
Expect SRZN to range from $39.66 to $100.04 through 2033. The $60.56 average target implies a +173% move from current prices. That is up +25% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SRZN price prediction for 2034 points to an average of $60.17 (low $38.55, high $101.32) — a potential gain of +171% on today's $22.21. Momentum favours further upside here.
In 2035, SRZN is projected to trade between $41.37 and $113.00, averaging $65.92 — a potential gain of +197% from today's $22.21. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Surrozen, Inc.'s 2040 outlook centres on $104.16, within a $59.37 to $192.26 range. That is up +58% on the projected 2035 average. That marks a +369% change versus current levels. Momentum favours further upside here.
By 2050, SRZN could reach as high as $365.63, with a base case around $178.15 and support toward $85.43 — roughly +702% from $22.21. Buyers look set to stay in control over this stretch.
Investing $1,000 in SRZN today (≈ 45.024764 SRZN) could be worth
$8,020.94
+$7,020.94 (+702%) by 2050 · US Dollar
Based on the average projected SRZN price of $178.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SRZNwould be worth at today's price.
$1,000 invested in SRZN on Jul 31, 2025 (≈ 100 SRZN) would be worth
$2,221
+$1,221 (+122.1%) today · 2.22× · US Dollar
Based on a SRZN entry price of $10 vs. today's $22.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.73 | $1,125.7 | +12.6% |
| 1 month ago | $25.52 | $870.3 | -13.0% |
| 3 months ago | $33.6 | $661.01 | -33.9% |
| 6 months ago | $22.1 | $1,004.98 | +0.5% |
| 1 year ago | $10 | $2,221 | +122.1% |
| All time (5.0y) ago | $149.55 | $148.51 | -85.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SRZN forecast.
Our base-case forecast reaches $44.00 around 2032.
Implied market cap at $44.00: $510.86M
The multi-year forecast lays out a bullish path from 2027 onward. The 2026 forecast shows a min of $17.98, an average of $20.83, and a max of $29.78 with a 0% ROI and neutral sentiment, suggesting a flat year around the current level. In 2027 the average rises to $26.61 with a 27.7% ROI and bullish sentiment, followed by 2028 with an average of $29.23 and 40.3% ROI; 2029 at $30.78 and 47.8% ROI.
The 2030 forecast projects an average of $32.26 with a 54.9% ROI, and 2031 at $32.99 with 58.4% ROI. By 2032, the average jumps to $42.67 and the max to $68.29, producing a 104.9% ROI with bullish sentiment, continuing through 2033 at $53.05 (154.7% ROI) and 2034 at $52.98 (154.3% ROI). The 2035 forecast shows $57.74 average and 177.2% ROI.
The long-horizon view extends to 2040 with an average of $89.25 and a 328.4% ROI, and to 2050 with an average of $151.07 and 625.3% ROI, both bullish. These figures are estimates and not guarantees. Risks and uncertainties apply, including market conditions and the inherent variability of biotech equities.
Tap a question to reveal the answer.
The 2030 forecast lists min $22.91, avg $32.26, max $49.21 with a 54.9% ROI and bullish sentiment.
The 2026 forecast shows avg $20.83 with 0% ROI and neutral sentiment; the outlook becomes bullish from 2027 onward with rising averages and ROIs.
Yes — the 2032 forecast max is $68.29, which includes a path above $50; the 2030 max is $49.21, so crossing $50 would occur by 2032 according to the forecast.
Current price is $20.83 and market cap is $241.84M.
For 2050, the forecast shows min $74.67, avg $151.07, max $304.98 with a 625.3% ROI and bullish sentiment.
Surrozen, Inc. Community Discussion
0Share your Surrozen, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.